Life Scientists Get Their Game Faces On



Borrowing technology from gamers, science speeds up. 

By Mike May

April 1, 2008 | A few years ago, Ryan Schneider, chief technology officer at Acceleware in Calgary, Alberta, and his colleagues were struggling to solve complex computing challenges such as biological-image reconstruction. Needing more speed than mere CPUs could provide, Schneider's team tried field programmable gate areas (FPGAs) and even Microsoft's Xbox, finally settling on graphics processing units (GPUs).

It turns out that GPUs accelerate more than games and graphics. GPUs - single-chip processors that provide extensive parallel programming - hit the PC market in 1999, handling graphics tasks, including rendering and transformation. "As compared to conventional CPUs, GPUs consist of high-bandwidth memories and more floating point-hardware units," says Dinesh Manocha, a professor in the department of computer science at the University of North Carolina at Chapel Hill. "For example, a current high-end GPU, such as the NVIDIA G80, has peak performance of 300 GFLOPS [billion floating point operations per second] for rasterization and memory bandwidth of 86 gigabytes per second. That compares to 50 GFLOPS and 6 gigabytes per second for a 3-GHz, multi-core Intel Core 2 CPU." Today's top-selling GPUs come from a trio of California companies: AMD in Sunnyvale, and Intel and NVIDIA, both in Santa Clara.

Beyond graphics rasterization, GPUs can also accelerate computationally intensive problems. "For those applications that map well to parallelization, there can be a tremendous speedup with little or no cost for hardware," says Jack Collins, manager of scientific computing and program development at the Advanced Biomedical Computing Center, which is run by SAIC for the National Cancer Institute in Frederick, Maryland. "This turns out to be highly beneficial since most every computer has a graphics card with GPUs that can be utilized." In short, GPU computing puts high-performance on almost anyone's desk.

Kudos for New Codes
Getting more than games or graphics rasterization out of GPUs, though, was initially a challenge. Programmers had to use application-programming interfaces (APIs), such as OpenGL or DirectX, to get general computing from a GPU. Developers also needed to understand the details and organization of GPU hardware. Moreover, an algorithm only runs fast on a GPU if a programmer modifies the algorithm and data structures to take advantage of a GPU's parallelism.

As Manocha says, "In order to utilize the computational power and memory bandwidth available in the GPUs, many novel algorithms have been designed that utilize the rasterization capabilities for non-graphics applications." Even better, scientists can now interact with a GPU through higher-level interfaces, including NVIDIA's CUDA (free for download at www.nvidia.com/cuda) and AMD's CTM (also free: ati.amd.com/companyinfo/researcher/resources.html).

Collins, for example, uses CUDA, which NVIDIA describes as a C language development environment. "You do not have to be a hardware expert to use CUDA," says Collins. "With CUDA, GPU programming is now much more accessible to the average programmer than in the past." Still, he says that leveraging the full benefits of GPU computing through CUDA requires restructuring code and probably revising the algorithm for the computation at hand.

Expanding Opportunities
NVIDIA provides various GPU systems. CUDA-enable graphics cards start at just $35 and run as high as $1299 for the Tesla C870, which was designed specifically for computation. "With our workstation products," says Andy Keane, general manager of the GPU computing business unit at NVIDIA, "it's like putting a 32- or 64-node computer on your desk. All you do is connect a cable to the PCI slot." NVIDIA also makes data-center systems.

Keane adds that CUDA goes beyond the GPU alone. "CUDA lets you mix the sequential processing on a CPU with the parallelism of GPUs," he says. "And multicore CPUs make the connection even easier. With more CPUs, you can use more GPUs." Moreover, NVIDIA plans to expand CUDA's capabilities, such as adding a FORTRAN interface.

Acceleware also makes software that works with GPUs. With Acceleware's tools, independent software vendors can bypass the details of GPU programming. Acceleware's hardware-software combinations range from $10,000-75,000. "We provide an API and a library to software vendors," says Schneider. He mentions that one large pharmaceutical company used Acceleware's libraries to reconstruct images. "With the company's old technology," says Schneider, "a single scan took about an hour and a half to reconstruct, and our product reduced that to 3-4 minutes."

With such scans, pharmaceutical scientists "can perform studies to look at the effects of compounds in a variety of disease models, such as neurological and oncological diseases, in addition to bone and musculosketal disorders," adds Alice Ford-Hutchinson, product manager for imaging at Acceleware.

Accelerating Applications
In 2006, Manocha's group used GPUs to take on a well-known database-sorting benchmark called Indy. They used a 3-GHz Pentium IV with a 7800GT NVIDIA graphics card to sort 590 million 100-byte records in under 11 minutes, which was a new record (see: http://research.microsoft.com/barc/SortBenchmark/).

GPUs can also be applied to many other bioinformatics tasks, including sequence alignment, pattern matching, and fluorescence microscopy. John Stone, a senior research programmer at the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-Champaign, and his colleagues use GPUs for molecular-dynamic simulations. He also uses CUDA, noting, "It only took about a day of programming to get our first piece of code ported to the GPU." But he adds, "We were using a hand-picked problem that I thought would map well to a GPU, and we are very experienced programmers." If code ports efficiently to a GPU, says Stone, it can speed it up by 30-100 times. "The worst case with GPUs," he says, "is around seven times, and that's not bad."

But whether researchers choose GPU computing, FPGAs, or supercomputers, Stone is adamant that code must move to parallel approaches. "Any algorithm that isn't parallel," says Stone, "is now a dead end."

___________________________________________________

 This article appeared in Bio-IT World Magazine.
Subscriptions are free for qualifying individuals.  
Apply Today.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .